Application of S100A8 as treatment target of vascular malformation
By using S100A8 as a binder for MS and enhancing its interaction with DDX24, the problem of the lack of effective treatment for MOVLD vascular malformations in the prior art was solved. This achieved the inhibition of endothelial cell migration and tube formation caused by DDX24 deficiency, thus enhancing the therapeutic effect of MS.
Patent Information
- Application Number
- CN202411008710.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-07-26
AI Technical Summary
There is currently no effective treatment for vascular malformations caused by multiple organ venous and lymphatic defects syndrome (MOVLD), and montelukast sodium (MS) may act through targets other than CysLT1R.
Using S100A8 as a binding agent for MS to treat vascular malformations caused by DDX24 knockdown, the interaction between S100A8 and DDX24 is promoted by enhancing the binding of MS to S100A8, stabilizing the expression of DDX24, and inhibiting endothelial cell migration and tube formation.
It effectively inhibits endothelial cell migration and tube formation caused by DDX24 deficiency, enhances the therapeutic effect of MS, and provides a new treatment option for vascular malformations.
Smart Images

Figure CN119033932A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of disease treatment, and more specifically, relates to the application of S100A8 as a therapeutic target for vascular malformations. Background Art
[0002] Montelukast sodium (MS) has long been considered a classic anti-inflammatory drug for the treatment of asthma. The mechanism by which MS exerts its efficacy is to target the cysteinyl leukotriene receptor (CysLTR1), which binds to leukotriene D4 (LTD4) and E4 (LTE4) to mediate inflammatory signaling. In addition to asthma and multiple sclerosis, MS is also used in a variety of cardiovascular diseases, such as atherosclerosis, myocardial infarction, and cardiac fibrosis.
[0003] Vascular malformations (VMs) are abnormalities in the formation of blood vessels that can occur in various types of blood vessels, such as arteries, veins, lymphatic vessels, or capillaries, and have a significant impact on patients' quality of life and mortality. In most cases, VMs are caused by abnormal vascular development, leading to altered angiogenesis. A new type of VM, called multiple organ venous and lymphatic defect syndrome (MOVLD syndrome), has been reported previously, and its symptoms mainly include stenosis or occlusion of the portal vein and hepatic vein, accompanied by the formation of collateral circulation. Currently, there is no effective treatment for MOVLD syndrome.
[0004] The Chinese patent application number 201910705697.5 discloses compounds for treating vascular malformations. The article points out that CysLTR1 antagonists, such as montelukastner, can upregulate the expression of DDX24 in vascular smooth muscle cells and have a certain therapeutic or ameliorative effect on vascular malformations; but interestingly, there is increasing evidence that CysLT1R is not the only cell target regulated by MS, such as the bile acid receptor GPBAR1, which is a new ligand for MS in macrophages and can reduce inflammation in colitis. This shows that in addition to CysLT1R, potential targets for MS and their underlying mechanisms remain to be explored. Summary of the invention
[0005] In order to overcome the deficiencies of the prior art, the present invention aims to provide the use of S100A8 as a therapeutic target for vascular malformations.
[0006] The purpose of the present invention is achieved through the following technical solutions:
[0007] Application of S100A8 as a binding agent for montelukastner in the treatment of vascular malformations caused by DDX24 knockdown.
[0008] The present study shows that MS (montelukastner) directly binds to the binding pocket of S100A8 with moderate affinity (Kd = 1.07 μM). S100A8 belongs to the largest subgroup of the Ca2+ binding EF-hand superfamily and is essential for calcium influx that affects endothelial cell migration and proliferation. It can be determined that S100A8 is a new MS binder that can effectively attenuate DDX24 deficiency-induced angiogenesis.
[0009] Preferably, in the above application, S100A8 is combined with montelukastina to enhance the therapeutic effect of montelukastina on vascular malformations caused by DDX24 knockdown.
[0010] Based on the premise of determining S100A8 as a therapeutic target for MS in treating vascular malformations, the present invention studied the therapeutic effect of overexpressing S100A8 on MS. The results showed that MS could inhibit the increase in endothelial migration induced by DDX24 deficiency, but overexpressing S100A8 could rescue the increase in endothelial migration caused by DDX24 knockdown; on the basis of overexpressing S100A8, MS could further inhibit the increase in endothelial migration induced by DDX24.
[0011] At the same time, MS can inhibit the increase in endothelial tube formation induced by DDX24 deficiency; overexpression of S100A8 can rescue the increase in endothelial tube formation caused by DDX24 knockdown; overexpression of S100A8 can inhibit the increase in endothelial cell tube formation caused by DDX24 deficiency.
[0012] In summary, it can be determined that S100A8 can enhance the efficacy of MS.
[0013] Therefore, the present invention also protects the use of a substance that promotes the expression of S100A8 in the preparation of a functional product for treating vascular malformations caused by DDX24 knockdown using montelukastner.
[0014] Preferably, the functional product acts as a potentiator of montelukastner in treating vascular malformations caused by DDX24 knockdown.
[0015] The present invention also protects the use of a substance that promotes the expression of S100A8 and montelukastner as a pharmaceutical composition in the preparation of a drug for treating vascular malformations caused by DDX24 knockdown.
[0016] Preferably, the substance that promotes the expression of S100A8 includes any one of the following:
[0017] (i) using S100A8 or S100A8 transcript as a target sequence and being able to enhance the expression of the S100A8 gene expression product;
[0018] (ii) a construct containing S100A8, or a sequence complementary to S100A8, and capable of forming an enhanced S100A8 gene expression product after being introduced into the body;
[0019] (iii) cells or constructs overexpressing the S100A8 gene sequence.
[0020] More preferably, the substance promoting the expression of S100A8 is a plasmid, a virus or a gene-edited cell overexpressing S100A8.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] The in vitro and in vivo experiments of the present invention verify the therapeutic effect of MS on DDX24-deficient vascular malformations. Immunoprecipitation results show that MS stabilizes the expression of DDX24 protein by inhibiting its ubiquitination in the cytoplasm. The direct binding target of MS in endothelial cells (ECs) was identified as S100 calcium-binding protein A8 (S100A8) by mass spectrometry technology, and verified by cell thermal shift assay (CETSA), drug affinity reaction target stability (DARTS), molecular docking simulation and surface plasmon resonance (SPR) analysis. Through direct interaction with S100A8, MS promotes the formation of a complex between S100A8 and the DDX24-Q motif. Our research reveals the new function of MS in treating vascular malformations through the new target S100A8, providing a new treatment option for the treatment of vascular malformations. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 Montelukast (MS) was shown to alleviate DDX24 deficiency-induced vascular malformations; Figure 1 A and Figure 1 B is the representative images (A) and quantification (B) of MS inhibition of vascular endothelial cell migration after DDX24 knockdown, scale bar 200 μm; Figure 1 C and Figure 1 D is the representative image (C) and quantification (D) of MS-inhibited endothelial cell tube formation after DDX24 knockdown, scale bar 200 μm; Figure 1 EG are representative images of ISV overbranching (E), abnormal ISV incidence (F), and abnormal ISV number (G) in zebrafish embryos injected with ddx24 morpholino after MS inhibition. White rectangles represent magnified views of local areas. Scale bar: 10 μm. Figure 1 H is Western blot showing the protein level of DDX24 in HUVECs transfected with DDX24 siRNA or control and treated with MS (10 μM) for 12 h; Figure 1I is Western blot showing the Ddx24 protein level in zebrafish embryos injected with ddx24 morpholino and treated with MS (10 μM) for 48 h; Figure 1 J and 1K are NSGs treated with MS after DDX24 knockdown TM Representative images of Matrigel (J) and blood vessel (CD31) staining in mice, magnified view of the local area indicated by the white box, scale bar 10 μm, n = 4; statistical analysis was performed using one-way ANOVA ( Figure 1 B, 1D, 1F, 1G, 1I, 1K), Student's t test ( Figure 1 H); All data are expressed as mean ± SEM; ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001;
[0024] Figure 2 It shows that MS has other targets besides CysLTR1; Figure 2 A is Western blot showing the protein level of CysLTR1 in HUVECs transfected with CysLTR1 siRNA or control; Figure 2 B is the representative images and quantification of HUVECs transfected with CysLTR1 siRNA or control by Transwell assay, scale bar 200 μm; Figure 2 C is a representative image and quantification of HUVECs transfected with CysLTR1 siRNA or control in the tube formation experiment, with a scale bar of 200 μm; one-way ANOVA was used for statistical analysis; all data are expressed as mean ± SEM; *P < 0.05, **P < 0.01;
[0025] Figure 3 showed that S100A8 is a direct target of MS; Figure 3 A is the chemical structure of biotin-conjugated montelukast; Figure 3 B is a flow chart of target screening; Figure 3 C is the mass spectrometry analysis of global proteins in HUVECs and the identification of S100A8 peptide; Figure 3 D is Western blot showing the expression of S100A8 protein in HUVECs treated with MS (10 μM) or control (DMSO) at the indicated temperatures (detected by CETSA); Figure 3 E is a Western blot showing the expression of S100A8 protein before and after digestion with 1 μg / mL enzyme E, and after HUVECs were treated with the indicated doses of MS for 1 h; Figure 3 F, SPR analysis showing direct interaction between MS and S100A8; Figure 3G is a schematic diagram of S100A8 and its mutants. The S100A8 mutant contains the deleted helical domain 1 (ΔH1) H: helix structure; Figure 3 H is the molecular simulation of the MS binding site S100A8; Figure 3 I is the SPR analysis of MS combined with S100A8-MUT;
[0026] Figure 4 S100A8 and DDX24 protein purification and affinity with MS are shown; Figure 4 A is the purified S100A8 protein in E. coli, SDS-PAGE (15% gel) was used to analyze S100A8-6xHIS by Ni-NTA column; the red rectangle indicates the location of the fusion protein S100A8-6xHIS (12.7 kDa); Figure 4 B The left figure is the chromatogram of the purified DDX24 protein through a superdex7516 / 600 gel filtration column; the right figure is the SDS-PAGE analysis of DDX24 through Ni-NTA exclusion chromatography, and the red rectangle indicates the position of the DDX24 protein; Figure 4 C is the SPR analysis of MS combined with DDX24;
[0027] Figure 5 Show validation of S100A8 knockdown in endothelial cells; Figure 5 A is Western blot showing the protein level of S100A8 in HUVECs transfected with S100A8 siRNA or control; Figure 5 B is RT-qPCR showing the expression of S100A8 mRNA in cells transfected with S100A8 siRNA or control; one-way ANOVA was used for statistical analysis; data are expressed as mean ± SEM; ns, no significance, *P < 0.05 and ***P < 0.001;
[0028] Figure 6 It was shown that MS binds to S100A8 to inhibit angiogenesis; Figure 6 A and Figure 6 B is the representative images (A) and quantification (B) of HUVECs transfected with S100A8 siRNA or control after MS treatment by Transwell assay, scale bar 200 μm, scale bar 200 μm; Figure 6 C and 6D are representative images (C) and quantification (D) of HUVECs treated with S100A8 siRNA or control in tube formation assay, scale bar 200 μm; Figure 6 E is Western blot showing the expression of DDX24 in HUVECs transfected with control or S100A8 siRNA, treated with MS (10 μM) or not treated for 12 h; Figure 6F is a fluorescence staining image showing the expression of DDX24 in HUVECs treated with MS (10 μM) or without MS for 12 h, scale bar 10 μm; Figure 6 G is Western blot showing DDX24 ubiquitination. After HEK293T cells were transfected with S100A8 siRNA or control, HA-ubiquitin and Flag-DDX24 were overexpressed and then treated with MG132 (2 μM) and / or MS (10 μM) for 12 h; Figure 6 H and 6I are representative images (H) and quantification (I) of HUVECs overexpressing S100A8 after transfection with S100A8 siRNA using the Transwell assay, with a scale bar of 200 μm; Figure 6 J and 6K are representative images (J) and quantification (K) of HUVECs transfected with S100A8 siRNA and overexpressing S100A8 in tube formation assays. Scale bar: 200 μm. Statistical analysis was performed using Student's t test ( Figure 6 B and 6D), one-way ANOVA (6I and 6K); all data are expressed as mean ± SEM; ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001;
[0029] Figure 7 showed that MS promoted the interaction between S100A8 and DDX24; Figure 7 A is Western blot showing the interaction between S100A8 and exogenous Flag-DDX24 in HEK293T cells; Figure 7 B is the co-IP analysis of the interaction between S100A8 and Flag-DDX24 in HUVECs before and after MS treatment; Figure 7 C is a representative image and white arrow of co-localization of S100A8 and DDX24 in HUVECs, scale bar 10 μm; Figure 7 D is a schematic diagram of full-length and truncated DDX24 transcripts; Figure 7 E is a Western blot showing that after being treated with MS (10 μM) for 12 h in HEK293T cells, co-IP detected the interaction between Myc-S100A8 and the designated fragments of Flag-DDX24; Figure 7 F and 7G are representative images of immunostaining showing the colocalization of endogenous S100A8 and transfected Flag-DDX24-N2 (F) or -C2 (G) in HUVECs. The inset on the right is the colocalization coefficient, and the scale bar is 10 μm.
[0030] Figure 8 showed that MS enhanced the interaction of exogenous DDX24 with S100A8; Figure 8 A is the immunoblot analysis of the interaction between exogenous Myc-S100A8 and Flag-DDX24 in HEK293T cells transfected with Flag-DDX24 and Myc-S100A8; Figure 8 B: Exogenous Flag-DDX24 co-localizes with Myc-S100A8 in HUVECs; Figure 8 C is a representative image of colocalization of DDX24-FL and S100A8 in endothelial cells, the right image is the colocalization coefficient, scale bar 10 μm;
[0031] Fig. 9 S100A8 was shown to enhance MS efficacy; Fig. 9 A is a representative image and quantification of HUVECs transfected with S100A8 siRNA or control and then overexpressed S100A8-Myc under MS by Transwell assay, scale bar 200 μm; Fig. 9 B shows the images and quantification of HUVECs treated with siS100A8 or control and then overexpressing S100A8-Myc under MS in the tube formation experiment. Scale bar, 200 μm. One-way ANOVA was used for statistical analysis. All data are expressed as mean ± SEM. ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. DETAILED DESCRIPTION
[0032] In order to better illustrate the purpose, technical scheme and advantages of the present invention, the present invention will be further described below in conjunction with specific drawings and embodiments. In the embodiments, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all commercially available unless otherwise specified.
[0033] Cell culture and cell lines: Human umbilical vein endothelial cells (HUVEC) were cultured in ECM supplemented with 10% fetal bovine serum. HUVEC were used for experiments up to passage 10. The medium was changed every other day and separated with TrypLESelect for passaging when confluence was reached. Human embryonic kidney 293T (HEK293T) cells were cultured in DMEM containing 10% fetal bovine serum, 1% penicillin and streptomycin. The above cells were cultured at 37°C in 5% CO2. Cells were authenticated by short tandem repeat (STR) analysis and confirmed to be free of mycoplasma contamination before use.
[0034] Animal experiments were approved by the institutional ethical guidelines for animal experiments established by the Fifth Affiliated Hospital of Sun Yat-sen University (#00498).
[0035] Zebrafish experiments: Embryos were collected by zebrafish mating and kept in E3 medium in an incubator at 28.5°C. For the zebrafish model lacking ddx24, 1.5 ng ddx24 MO (5'-TAATCTCTGTGCCCCTACCGTCTTC-3') was injected into the yolk in 1- to 4-cell stage embryos. Healthy embryos were selected into 6-well plates at 6 hours post fertilization (hpf) and exposed to different concentrations of MS treatment, with 0.1% DMSO as a control. The images were collected under a stereomicroscope at the time point of 54 hpf to record the development of the embryos. When performing pharmacological experiments and mechanism validation of MS experiments, the Tg (fli1a: EGFP) transgenic strain was used. Two researchers were involved in the embryo experiments: one researcher injected embryos and applied MS to zebrafish embryos, and the other researcher recorded the phenotypes of the embryos, performed s statistics and took pictures without clarifying the experimental grouping.
[0036] Mouse experiment: 12 NSG mice were enrolled in the experiment TM Mice. These mice were divided into three groups: DDX24 NC, DDX24 deficient, and DDX24 deficient + MS. Matrigel containing pre-treated endothelial cells, PBS (0.2 ml) and vascular endothelial growth factor (VEGF; 500 ng / ml) was mixed. The mixed Matrigel was then injected subcutaneously into 6-8 week old NSGs. TM The flank of the mouse was injected with 0.2 ml per mouse. 14 days after injection, the matrix gel plugs were harvested and photographed. Endothelial cells were stained with the marker CD31 by immunofluorescence on 10 μm sections embedded in OCT. Three researchers participated in the embryo experiment: one researcher who injected the MS and two researchers who performed dissection, photography and immunofluorescence observation.
[0037] Gene knockdown and plasmid overexpression: DDX24 or S100A8 siRNA was transfected with LTX (Invitrogen) to generate DDX24 or S100A8 knockdown cells. For plasmid transfection, Lipo3000 was used, and 10 μg of plasmid was transfected per 10 cm dish to transfect 70% confluent cells. Human DDX24 fused to a C-terminal Flag tag and S100A8 fused to a Myc tag were obtained from IGE BIO. Cell lysates were collected 12 hours (h) after MS treatment and analyzed by Western blot.
[0038] Immunoprecipitation and Western blotting: Pierce TMThe Co-IP Kit uses anti-DDX24 antibody for endogenous DDX24 Co-IP detection. Normal rabbit IgG was used as a control. Exogenous Co-IP complexes were detected with anti-Flag or anti-Myc antibodies. The samples were then boiled and analyzed by western blotting. For western blotting, samples were separated by SDS-PAGE and then electrotransferred to polyvinylidene fluoride (PVDF) filters. The PVDF membrane was blocked in TBST (0.1% Tween 20, 50mM Tris-HCl (pH 7.4), and 150mM NaCl) containing 5% skim milk for 1 hour, followed by incubation with the primary antibody at 4°C overnight. The membrane was incubated with the corresponding secondary antibody the next day and detected using ECL reagent.
[0039] Immunofluorescence microscopy: Cells were seeded into 15 mm glass-bottom confocal dishes and fixed in 4% paraformaldehyde for 15 min at room temperature before staining. The slides or dishes were then incubated in TBST (TBS containing 0.1% Triton X-100) for 10 min, blocked (10% goat serum + 1% BSA + 0.05% Tween 20) for 1 h at room temperature, and then incubated with various primary antibodies overnight at 4 °C. Alexafluor 488-conjugated goat anti-rabbit (BOSTER, BA1126) and Alexafluor 555-conjugated goat anti-mouse IgG (Bioss, bs-0296G-AF555) were used. Slides were mounted with DAPI-conjugated antifade mounting medium (Solarbio, S2110) before analysis with a Zeiss 880 confocal laser scanning microscope.
[0040] Purification of recombinant protein: The full-length human S100A8 (S100A8-wt) transcript variant gene (NCBI reference sequence: NP_0029559.2) or S100A8 mutant was fused with a 6x His tag and subcloned into the pET-28a (+) vector. The plasmid was transformed into BL21 (DE3) competent cells (11804ES80, Yeasen) by induction with 200 μM IPTG at 16 ° C for 16 hours. The cells were harvested by centrifugation. All purification steps were performed on ice. The cell pellet was resuspended and sonicated in a lysis buffer consisting of buffer A (20mM Tris-HCl, pH 8.0, 500mM NaCl, 25mM imidazole) and loaded onto a Ni-NTA column washed with buffer B (20mM Tris-HCl, pH 8.0, 500mM NaCl, 50mM imidazole-HCl, pH 8.0). The bound protein was eluted from the column by buffer C (20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 500 mM imidazole-HCl, pH 8.0). The desired protein was finally purified by size exclusion chromatography in HEPES (N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid) buffer (10 mM HEPES, pH 8.0; 150 mM NaCl). For the DDX24 protein, the experiment was performed according to existing literature.
[0041] Cellular thermal shift (CETSA) assay: HUVEC or HEK293T cells were cultured in 10 cm dishes, treated with DMSO or MS (10 μM) for 1 hour, and resuspended in PBS supplemented with protease inhibitors. The samples were divided into 8 parts, heat-treated at 41, 44, 47, 50, 53, 56, 59, and 63 ° C for 5 minutes, freeze-thawed in liquid nitrogen for 3 times, and centrifuged to obtain the supernatant. SDS-PAGE loading buffer was added. The samples were analyzed by immunoblotting.
[0042] Drug affinity reactive target stability (DARTS) assay: HUVEC or HEK293T cells were lysed in RIPA buffer at a ratio of 4-6 mg / ml. The lysate was then treated with different concentrations of MS or DMSO for 1 h at room temperature. Cells were rapidly proteolyzed with 1 μg / mL Pronase E (Roche, 10165921001) at 25°C for 10 min, SDS-PAGE loading buffer was added and incubated at 95°C for 10 min. Proteins and proteolytic fragments were separated by SDS-PAGE and detected by Western blotting using anti-S100A8 antibody (R&D, MAB4570) or anti-Myc antibody (Vazyme, RA1005-01).
[0043] Computer modeling: Molecular docking studies were performed using Schrodinger 2018.1 / Glide. The crystal structure of S100A8 (PDB code: 5HLO) was downloaded from the RCSB Protein Data Bank and prepared using the Protein Preparation Wizard panel implemented in Maestro 10.5: water molecules were removed, missing hydrogens and residues were added. The binding site was then defined; compound MS was generated by Maestro13.1 and then docked to the S100A8 binding site using Glide in XP mode. All docking results were processed by Maestro 13.1 and PyMOL software.
[0044] Surface plasmon resonance (SPR) assay: The interaction between immobilized MS and His-S100A8 or DDX24 was detected using a Biacore T200 instrument. The experiments were performed as described previously23. Briefly, purified DDX24 or S100A8 proteins were dissolved to 0.05 mg / ml in 10 mM NaOAc (sodium acetate) buffer (pH 4.5) and then immobilized on a CM5 chip with approximately 10,000 response units (RU) by amine coupling according to the manufacturer's instructions (GE Healthcare). Binding curves were obtained by first flowing the protein sample at 30 μL / min for 300 seconds for association, then flowing with running buffer for 300 seconds for dissociation, and then flowing at 30 μL / min for 60 seconds for regeneration. MS-containing masterbatch was diluted with PBS without DMSO using an isocratic dilution method to obtain MS protein (S100A8 or DDX24) RU. The dissociation constants (Kd) of the compounds and proteins were fitted according to a standard 1:1 binding model and then obtained by global fitting of the kinetic data of compound gradient concentrations.
[0045] mRNA stability assay: Cells were pretreated with or without MS for 12 h (TargetMol, A4448-5 mg) before adding actinomycin-D at a final concentration of 50 μg / mL. Total mRNA was extracted and quantified by real-time RT-PCR at 3, 6, and 9 h after treatment. Results were normalized relative to 0 h.
[0046] Tube formation experiment: After the cells reach 60% to 70% confluence, they are ready for transfection. First, they are transfected with DDX24 siRNA to knock down the cells. After 6 hours, fresh culture medium is replaced. After 24 hours, the cells are infected with virus supernatant containing S100A8-Myc. After 6 hours, fresh culture medium is replaced. 50 μL of matrix gel is spread on a pre-cooled 96-well plate and placed at 37°C for 30 minutes. Digest and collect cells for counting. 100 μL of HUVEC cell suspension is added to the 96-well plate, with a concentration of about 1.3 million cells. DMSO-containing culture medium and MS (2.5 μmol / L) are added respectively, and the plates are placed in a 37°C incubator for about 6 to 8 hours to observe whether blood vessels are formed. Take photos and record. The experiment is repeated three times.
[0047] Cell migration assay: After the cells reached 60% to 70% confluence, they were ready for transfection. They were first transfected with DDX24 siRNA to knock down the cell, and fresh medium was replaced after 6 hours. After 24 hours, the cells were infected with the virus supernatant containing S100A8-Myc, and fresh medium was replaced after 6 hours. After 48 hours of infection, the cells were digested and resuspended in serum-free medium, and the cell density was adjusted to (7-8)×10 5 / mL, remove the Millicell insert chamber under sterile conditions and place it in a sterile 24-well culture plate. Add 600μL of the same concentration of DMSO or MS (2.5μmol / L) to the 24-well plate. Take 300μL of the cell suspension and place it in the upper chamber of the Transwell. Put the culture plate with the cell suspension into the normal culture state (5% CO2, 95% O2) to culture the cells for 12h. Then take out the insert chamber, gently wipe the cells on the inner surface of the filter membrane of the upper chamber with a cotton swab, put the entire insert chamber into the 24-well plate, fix it with 95% alcohol for 15min, and stain it with 0.1% crystal violet for 20min; count the number of cells that pass through the membrane, and repeat the whole experiment 3 times.
[0048] Example 1 Montelukast can eliminate DDX4 deficiency-induced vascular malformations
[0049] The effect of MS in DDX24-deficient cells was first investigated in vitro. Cell migration results showed that MS reversed the increased cell migration after DDX24 knockdown ( Figure 1 A and 1B). Similarly, the tube formation experiment reflects the results of cell migration ( Figure 1 C and 1D). However, MS treatment did not affect the proliferation capacity of HUVECs. These data suggest that MS inhibits DDX24 deficiency-induced angiogenesis.
[0050] To investigate the effects of MS on VM in vivo (MOVLD), transgenic zebrafish Tg(fli1a:EGFP) embryos were injected with ddx24 MO in 1-4 cells. After treatment with DMSO or 2.5, 5, and 10 μM MS for 48 h, we found that the resulting hyperbranched intersegmental vessels (ISVs) had a phenotype similar to that of MOVLD patients ( Figure 1 E-1G). As expected, the abnormalities caused by Ddx24 deficiency were rescued by MS treatment. Based on the above results, MS may upregulate DDX24 protein expression. In fact, after MS treatment, DDX24 protein levels were increased in both DDX24-deficient HUVECs and zebrafish embryos ( Figure 1 H and 1I).
[0051] To further validate the effect of MS on VM in mammalian models, we performed Matrigel plug assays in mouse models and showed that excessive angiogenesis caused by DDX24 deficiency could be completely abolished by MS treatment ( Figure 1 J and 1K). Taken together, the above results indicate that DDX24 deficiency leads to excessive angiogenesis and ISV hyperbranching in zebrafish endothelial cells, which can be alleviated by MS treatment.
[0052] Example 2 S100A8 is a direct target of montelukastner
[0053] The classic mechanism of MS is to target a known protein, cysteinyl leukotriene receptor 1 (CysLTR1). To test whether the effects of MS on endothelial cells are dependent on CysLTR1, the receptor was depleted using a siRNA approach and analyzed by Western blotting ( Figure 2 A) Validation. Knockdown of CysLTR1 inhibits cell migration and tube formation ( Figure 2 B and 2C). Unexpectedly, MS treatment further attenuated cell migration, suggesting that MS may exert its anti-angiogenic function through alternative targets other than CysLTR1 or beyond CysLTR1.
[0054] To explore protein targets directly associated with MS, we conjugated montelukast to biotin and performed pull-down experiments in HUVECs followed by mass spectrometry analysis ( Figure 3 A). We identified 28 biotin-MS target proteins in two biological replicates, which were mainly enriched in the regulation of tissue migration and binding pathways. On the other hand, we also examined proteins that can bind to DDX24 using a pull-down assay, as DDX24 may be a downstream target of MS ( Figure 3 B) By overlapping the proteins detected by the above two methods, only one protein S100A8 located in the cytoplasm or membrane was obtained ( Figure 3C). This protein is known for its function in regulating macrophage migration and is closely associated with inflammatory processes and immune responses. Therefore, we focused our further studies on S100A8.
[0055] To verify that S100A8 is a bona fide binding partner of MS, a cellular thermal shift assay was performed. Compared with S100A8 treated with DMSO, S100A8 treated with MS showed increased stability at higher temperatures ( Figure 3 D). Furthermore, S100A8 was found to be more resistant to Pronase E-induced proteolysis after MS treatment as assessed by the drug affinity responsive target stability (DARTS) assay ( Figure 3 E). To further demonstrate the binding affinity between MS and S100A8, surface plasmon resonance (SPR) detection was applied after purification of S100A8 and DDX24 proteins ( Figure 4 A). The data showed that the dissociation constant (Kd) of S100A8 was 1.07 μM ( Figure 3 F), while the Kd of DDX24 was 15.79 μM ( Figure 4 B).
[0056] In addition, to determine the MS binding region on the S100A8 protein (PDB code: 5HLO-B), we performed molecular docking using Schrodinger software. The docking model showed that the carboxyl group of compound MS, as a hydrogen bond donor, could form a hydrogen bond with SER11 located in Helix1 at a distance of ( Figure 3 G). In addition to strong hydrogen bonding interactions, the quinoline ring and the benzene ring can also interact hydrophobically with residues PHE67, PHE71, and VAL75 in the S100A8 binding site. When the Helix1 domain in S100A8 is deleted (S100A8-MUT), it cannot bind to MS ( Figure 3 H and 3I, Figure 4 C). Overall, our multidimensional data suggest that S100A8 is a direct protein target of MS.
[0057] Example 3: MS binds to S100A8 to inhibit angiogenesis
[0058] To confirm whether the inhibition of angiogenesis by MS depends on S100A8, we knocked down S100A8 in HUVECs and verified it by WB and RT-qPCR ( Figure 5 A and 5B). We found that in the absence of S100A8, MS treatment did not alter cell migration and tube formation ( Figure 6To further confirm that the effect of MS on DDX24 expression is dependent on S100A8, we demonstrated that S100A8 deficiency abolished the accumulation of DDX24 protein in the cytoplasm after MS treatment using Western blot and IF analysis ( Figure 6 E and 6F). Knockdown of S100A8 alleviated the MS-induced decrease in DDX24 protein ubiquitination ( Figure 6 G). In terms of cell function, transfection of S100A8-WT can rescue the effects of MS in S100A8-deficient HUVECs ( Figure 6 H~6I). In contrast, transfection of S100A8-MUT failed to restore the effects of MS ( Figure 6 J-6K). Thus, these data indicate that S100A8 is critical for the effects of MS on DDX24 regulation and angiogenesis.
[0059] Example 4 MS stabilizes DDX24 by promoting the interaction between S100A8 and the Q motif of DDX24
[0060] Next, we sought to further investigate the MS-mediated interaction between S100A8 and DDX24. S100A8 is able to pull down DDX24 ( Figure 7 A). Furthermore, co-IP and IF experiments showed that higher DDX24 levels correlated with higher binding of S100A8 protein in the cytoplasm and that MS enhanced this interaction ( Figure 7 B and 7C; Figure 8 To further identify the region of DDX24 that interacts with S100A8, different DDX24 domains were truncated and tested for their binding to S100A8 ( Figure 7 D). Co-IP data showed that DDX24 interacted with S100A8 mainly through the Q motif ( Figure 7 E). Therefore, we transfected cells with full-length (FL), N2 (with Q motif), or C2 (without Q motif) of DDX24 protein and examined the colocalization of these fragments with S100A8. IF results confirmed that the Pearson correlation coefficient of DDX24 N2 with S100A8 was the same as that of DDX24 FL ( Figure 7 F and 8C), while the colocalization between DDX24C2 and S100A8 was severely hampered ( Figure 7 G). Overall, these data suggest that MS promotes the interaction between DDX24 and S100A8 primarily through the Q motif of DDX24.
[0061] Example 5 S100A8 can enhance the therapeutic effect of MS on vascular malformations induced by DDX4 deficiency
[0062] We have previously demonstrated that S100A8 is a target for the treatment of DDX4 deficiency-induced vascular malformations in MS. The lack of S100A8 has no therapeutic effect on DDX4 deficiency-induced vascular malformations in MS. Next, we investigated the therapeutic effect of overexpressing S100A8 on MS.
[0063] The results show that Fig. 9 A shows that MS can inhibit the increase in endothelial migration induced by DDX24 deficiency (comparison of the first three columns), but overexpression of S100A8 can rescue the increase in endothelial migration caused by DDX24 knockdown (comparison of the second and fourth columns in the presence of MS); on the basis of overexpression of S100A8, MS can further inhibit the increase in endothelial migration induced by DDX24. The results show that S100A8 can enhance the therapeutic effect of MS.
[0064] like Fig. 9 B shows that MS can inhibit the increase in endothelial tube formation induced by DDX24 deficiency (comparison of the first three columns of figures); overexpression of S100 can rescue the increase in endothelial tube formation caused by DDX24 knockdown (comparison of the second and fourth columns of figures); overexpression of S100A8 can inhibit the increase in endothelial cell tube formation caused by DDX24 deficiency (in the presence of MS), which means that S100A8 can enhance the efficacy of MS (comparison of the third and fifth columns of figures).
[0065] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. Application of S100A8 as a binder of montelukastner for the treatment of vascular malformations caused by DDX24 knockdown.
2. The use according to claim 1, characterized in that: S100A8 binds to montelukastine and enhances the therapeutic effect of montelukastine on vascular malformations caused by DDX24 knockdown.
3. Application of substances that promote S100A8 expression in the preparation of functional products for the treatment of vascular malformations caused by DDX24 knockdown using montelukastena.
4. The use according to claim 3, characterized in that: The functional product acts as a potentiator of montelukastner in treating vascular malformations caused by DDX24 knockdown.
5. Use of a substance that promotes S100A8 expression and montelukastner as a pharmaceutical composition in the preparation of a drug for treating vascular malformations caused by DDX24 knockdown.
6. The use according to any one of claims 3 to 5, characterized in that: The substance that promotes the expression of S100A8 includes any one of the following: (i) using S100A8 or S100A8 transcript as a target sequence and being able to enhance the expression of the S100A8 gene expression product; (ii) a construct containing S100A8, or a sequence complementary to S100A8, and capable of forming an enhanced S100A8 gene expression product after being introduced into the body; (iii) cells or constructs overexpressing the S100A8 gene sequence.
7. The use according to claim 6, characterized in that: The substance promoting the expression of S100A8 is a plasmid, a virus and a gene-edited cell that overexpresses S100A8.
Citation Information
Patent Citations
Compound for treating vascular malformation
CN110496124A
Application of vascular smooth muscle cell specificity DDX24 and downstream molecule thereof in vascular development
CN115245575A
